1. PURPOSE PURPOSE METHODSMETHODS CONCLUSIONSCONCLUSIONS Long-term results of daily HDR brachytherapy in the postoperative setting of endometrial carcinoma. Long-term results of daily HDR brachytherapy in the postoperative setting of endometrial carcinoma. RESULTSRESULTS TreatmentTreatment Castilla L 1, Rovirosa A 1, Ríos I 2, Arenas M 3, Sabater S 4, Camacho C 1, Vargas A 1 Llorente R 1, Valduvieco I 1, Biete A 1. 1-Radiation Oncology Dpts, Hospital Clínic, Barcelona; 2-Centro Médico Imbanaco, Cali, Colombia; 3-Radiation Oncology Dpt, Hospital Sant Joan de Reus, Tarragona; 4-Hospital General de Albacete, Albacete. Spain.  The present brachytherapy schedule for the postoperative treatment of EC of 2 fractions of 5 Gy after EBI and 4 fractions of 5 Gy administered on a daily basis is a safe regime in terms of local control and toxicity. Similar results were found in a previous series with an increased number of fractions. 153 p with EC staged after surgery as 2009 FIGO stage I-IIIC from January 2007 to September 2011 were treated with HDRBT after surgery and were the subject of the analysis.  Median age : Group 1: 65 (40-88); Group 2: 62 (39-90)  Mean and median follow-up(months):Group 1: 47.51 (8.64-82.149); Group 2: 48.08 (11.99-96.66).  Pathological characteristics of the series (Table 1).  VCR: Only 2 patients in Group 1 (2.12%) and no patients in group 2(0%). To analyze the long term results of daily high dose-rate brachytherapy (HDRBT) in vaginal-cuff relapses (VCR) and toxicity in postoperative endometrial carcinoma (EC). Table Nº 1: Pathologic characteristics of the series Stage (2009 FIGO) IA IB II IIIA IIIB IIIC1 IIIC2 Group 1: n=94(%) 5 (5.3) 45 (47.9) 14 (14.9) 13 (13.8) 2 (2.1) 10 (10.6) 5 (5.3) Group 2: n= 59(%) 33 (55.9) 24 (40.7) 2 (3.4) Pathology Endometrioid Clear cells Serous Mixed 64 (68.1) 3 (3.2) 2 (2.1) 25 (26.6) 48 (81.3) 2 (3.4) 7 (11.9) Grade 1 2 3 18 (9.1) 36 (40.0) 40 (42.6) 21 (35.0) 29 (48.3) 10 (16.7) Myometrial Invasion No < 50% ≥ 50% 0 (0) 77 (81.9) 17 (18.1) 5 (8.3) 24 (40.0) 31 (51.7) Median tumor size 4 (0.4-12) 3.4 (0.2-6) VLSI No Yes 63 (67.0) 31 (33.0) 50 (83.3) 9 (16.7) Table Nº2: Toxicity in Organs at risk(OAR) considering the shedule and EBI + BT vs BT alone. Statistical analysis  Surgery: Vaginal hysterectomy + bilateral salpingo-oophorectomy and pelvic with or without paraaortic lymphadenectomy by laparoscopy 42.5%; Abdominal hysterectomy + bilateral salpingo- oophorectomy and pelvic lymphadenectomy: 26.8%; Other: 30.7%  Radiotherapy (RT): Group 1: 94/153 External beam irradiation (EBI) (mean 45 Gy, range 44-50.4)+ HDRBT (2 fractions of 5-6 Gy); Group 2: 59/153 HDRBT alone (4 fractions of 5-6 Gy).  In Intermediate-risk EBI was administered when presence of pathological type other than endometrioid, vascular and lymphatic space invasion (VLSI) and/or tumor size>3cm. EBI was administered in patients with high risk and advanced stages.  Postoperative chemotherapy : 26 patients (4 cycles of carboplatin+paclitaxel).  Toxicity evaluation: Toxicity was prospectively evaluated using the RTOG score for the rectum and bladder and objective criteria of LENT-SOMA for the vagina.  Statistics: Statistical methods. The Chi-square method and the Fisher exact tests for survival analysis were used. The confidence interval was calculated at 95% and a 5% α error was used for statistical tests.  Toxicity. Acute and late toxicity are shown in table 2.  Significant differences between Groups 1 and 2 were only found in rectal toxicity (p=0.004). OARGroup 1Group 2 AcuteLateAcuteLate Vagina2.1% (G1)27.7% (all G1-2 but 1 G4) 6.6% (G1-2) 27,7% (G1-2) Bladder7.5% (G1-2) 1,1% (G1)6,7% (G1-2) - Rectum5.3% (G1-2) 7.3% (all G1-2 but 1 G3) --